MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- STRIDES PHARMA SCIENCE - PANACEA BIOTECH
STRIDES PHARMA SCIENCE vs PANACEA BIOTECH - Comparison Results
STRIDES PHARMA SCIENCE Change
Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More
PANACEA BIOTECH 
Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
Current Valuations
| STRIDES PHARMA SCIENCE | PANACEA BIOTECH | STRIDES PHARMA SCIENCE/ PANACEA BIOTECH |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 22.0 | 8.9 | 247.2% | View Chart |
| P/BV | x | 2.1 | 3.5 | 59.5% | View Chart |
| Dividend Yield | % | 0.2 | 0.0 | - |
Financials
 STRIDES PHARMA SCIENCE  PANACEA BIOTECH |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| STRIDES PHARMA SCIENCE Mar-18 |
PANACEA BIOTECH Mar-19 |
STRIDES PHARMA SCIENCE/ PANACEA BIOTECH |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,147 | 354 | 324.4% | |
| Low | Rs | 642 | 138 | 464.5% | |
| Sales per share (Unadj.) | Rs | 317.2 | 74.6 | 425.5% | |
| Earnings per share (Unadj.) | Rs | 7.8 | 6.7 | 117.4% | |
| Cash flow per share (Unadj.) | Rs | 25.1 | 15.5 | 161.7% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.2 | 0 | - | |
| Book value per share (Unadj.) | Rs | 274.3 | 57.2 | 479.4% | |
| Shares outstanding (eoy) | m | 89.50 | 61.25 | 146.1% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.8 | 3.3 | 85.5% | |
| Avg P/E ratio | x | 114.0 | 36.8 | 309.7% | |
| P/CF ratio (eoy) | x | 35.7 | 15.9 | 225.0% | |
| Price / Book Value ratio | x | 3.3 | 4.3 | 75.9% | |
| Dividend payout | % | 25.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 80,058 | 15,061 | 531.5% | |
| No. of employees | `000 | 2.5 | 2.3 | 108.3% | |
| Total wages/salary | Rs m | 4,341 | 1,471 | 295.1% | |
| Avg. sales/employee | Rs Th | 11,325.8 | 1,973.6 | 573.9% | |
| Avg. wages/employee | Rs Th | 1,731.4 | 635.6 | 272.4% | |
| Avg. net profit/employee | Rs Th | 280.1 | 176.8 | 158.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 28,394 | 4,567 | 621.7% | |
| Other income | Rs m | 941 | 45 | 2,099.6% | |
| Total revenues | Rs m | 29,334 | 4,612 | 636.1% | |
| Gross profit | Rs m | 3,965 | 2,030 | 195.4% | |
| Depreciation | Rs m | 1,540 | 540 | 285.3% | |
| Interest | Rs m | 1,962 | 1,048 | 187.2% | |
| Profit before tax | Rs m | 1,403 | 486 | 288.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | -168 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -436 | 0 | - | |
| Tax | Rs m | 97 | 77 | 126.2% | |
| Profit after tax | Rs m | 702 | 409 | 171.6% | |
| Gross profit margin | % | 14.0 | 44.4 | 31.4% | |
| Effective tax rate | % | 6.9 | 15.9 | 43.7% | |
| Net profit margin | % | 2.5 | 9.0 | 27.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 24,836 | 2,415 | 1,028.6% | |
| Current liabilities | Rs m | 18,993 | 9,077 | 209.2% | |
| Net working cap to sales | % | 20.6 | -145.9 | -14.1% | |
| Current ratio | x | 1.3 | 0.3 | 491.6% | |
| Inventory Days | Days | 71 | 65 | 109.0% | |
| Debtors Days | Days | 113 | 71 | 159.9% | |
| Net fixed assets | Rs m | 34,289 | 8,333 | 411.5% | |
| Share capital | Rs m | 895 | 61 | 1,460.0% | |
| "Free" reserves | Rs m | 23,651 | 3,443 | 687.0% | |
| Net worth | Rs m | 24,546 | 3,504 | 700.5% | |
| Long term debt | Rs m | 15,513 | 461 | 3,363.7% | |
| Total assets | Rs m | 65,437 | 13,755 | 475.7% | |
| Interest coverage | x | 1.7 | 1.5 | 117.2% | |
| Debt to equity ratio | x | 0.6 | 0.1 | 480.2% | |
| Sales to assets ratio | x | 0.4 | 0.3 | 130.7% | |
| Return on assets | % | 4.1 | 10.6 | 38.4% | |
| Return on equity | % | 2.9 | 11.7 | 24.5% | |
| Return on capital | % | 6.9 | 38.7 | 17.8% | |
| Exports to sales | % | 0 | 20.9 | 0.0% | |
| Imports to sales | % | 0 | 8.1 | 0.0% | |
| Exports (fob) | Rs m | NA | 954 | 0.0% | |
| Imports (cif) | Rs m | NA | 372 | 0.0% | |
| Fx inflow | Rs m | 15,697 | 1,203 | 1,304.8% | |
| Fx outflow | Rs m | 735 | 467 | 157.6% | |
| Net fx | Rs m | 14,962 | 736 | 2,031.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,871 | 1,049 | 178.4% | |
| From Investments | Rs m | 5,826 | -54 | -10,889.5% | |
| From Financial Activity | Rs m | -10,157 | -1,011 | 1,004.2% | |
| Net Cashflow | Rs m | -2,615 | -20 | 13,273.6% | |
Share Holding
| Indian Promoters | % | 27.7 | 74.5 | 37.2% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 37.8 | 0.6 | 6,300.0% | |
| FIIs | % | 8.6 | 1.3 | 661.5% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 25.9 | 23.6 | 109.7% | |
| Shareholders | 56,241 | 10,259 | 548.2% | ||
| Pledged promoter(s) holding | % | 0.0 | 35.1 | - |
Compare STRIDES PHARMA SCIENCE With: SHASUN PHARMA WYETH ABBOTT INDIA SUVEN LIFE SCIENCES DR. REDDYS LAB
Compare STRIDES PHARMA SCIENCE With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Crucial Week Ahead for the Indian Stock Market(Momentum Moves)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
Related Views on News
STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)
Aug 20, 2020 | Updated on Aug 20, 2020For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)
Nov 1, 2019 | Updated on Nov 1, 2019For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)
Jul 31, 2019 | Updated on Jul 31, 2019For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)
May 13, 2019 | Updated on May 13, 2019For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)
Mar 27, 2019 | Updated on Mar 27, 2019Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.
More Views on NewsMost Popular
Why Gold Hit Lower Circuit(Fast Profits Daily)
Jan 11, 2021Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Time to Book Profits in Pharma Stocks(Fast Profits Daily)
Jan 15, 2021In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)
Jan 11, 2021Our ace stock picker is ready to capitalise on a big growth opportunity.
Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)
Jan 15, 2021The pandemic failed to thwart Richa's investing success formula for 2020.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
STRIDES PHARMA SCIENCE SHARE PRICE
Jan 22, 2021 (Close)
TRACK STRIDES PHARMA SCIENCE
- Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON STRIDES PHARMA SCIENCE
STRIDES PHARMA SCIENCE - NATCO PHARMA COMPARISON
COMPARE STRIDES PHARMA SCIENCE WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.